ES2192535T3 - Derivados de n-(indolcarbonil)-piperazina como ligandos del receptor 5-ht2a. - Google Patents

Derivados de n-(indolcarbonil)-piperazina como ligandos del receptor 5-ht2a.

Info

Publication number
ES2192535T3
ES2192535T3 ES00949288T ES00949288T ES2192535T3 ES 2192535 T3 ES2192535 T3 ES 2192535T3 ES 00949288 T ES00949288 T ES 00949288T ES 00949288 T ES00949288 T ES 00949288T ES 2192535 T3 ES2192535 T3 ES 2192535T3
Authority
ES
Spain
Prior art keywords
hal
het1
independently
carbon atoms
mean
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00949288T
Other languages
English (en)
Inventor
Henning Bottcher
Hartmut Greiner
Jurgen Harting
Gerd Bartoszyk
Christoph Seyfried
Amsterdam Christoph Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2192535T3 publication Critical patent/ES2192535T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Compuestos de la fórmula I donde R1 significa un resto fenilo o naftilo insubstituidos o substituidos por R2 y/o R3, o Het1, R2, R3 significan respectivamente, de manera independiente entre sí, Hal, A, OA, OH o CN, R4, R5 significan respectivamente, de manera independiente entre sí, H, CN, acilo, Hal, A, OA, OH, CONH2, CONHA o CONA2, R4 y R5 significan también, conjuntamente, alquileno con 3 a 5 átomos de carbono, Het1 significa un sistema anular heterocíclicos, insaturado, mononuclear o dinuclear insubstituido o substituido una o dos veces por Hal, A, OA o OH, que contiene uno, dos o tres heteroátomos iguales o diferentes tales como nitrógeno, oxígeno y azufre, A significa alquilo con 1 a 6 átomos de carbono, Hal significa F, Cl, Br o I, y pudiendo estar reemplazado el anillo de indol también por una unidad de isatina, así como sus sales y solvatos fisiológicamente aceptables, quedando excluida la (1H - indol - 5 - il) - (4 - fenetil - piperazin - 1 - il) - metanona.
ES00949288T 1999-07-22 2000-07-07 Derivados de n-(indolcarbonil)-piperazina como ligandos del receptor 5-ht2a. Expired - Lifetime ES2192535T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19934433A DE19934433A1 (de) 1999-07-22 1999-07-22 N-(Indolcarbonyl-)piperazinderivate

Publications (1)

Publication Number Publication Date
ES2192535T3 true ES2192535T3 (es) 2003-10-16

Family

ID=7915702

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00949288T Expired - Lifetime ES2192535T3 (es) 1999-07-22 2000-07-07 Derivados de n-(indolcarbonil)-piperazina como ligandos del receptor 5-ht2a.

Country Status (26)

Country Link
US (2) US6838461B1 (es)
EP (1) EP1198453B9 (es)
JP (2) JP5242871B2 (es)
KR (1) KR100779207B1 (es)
CN (1) CN1229345C (es)
AR (1) AR024819A1 (es)
AT (1) ATE236877T1 (es)
AU (1) AU770411B2 (es)
BR (1) BR0012607A (es)
CA (1) CA2383779C (es)
CZ (1) CZ300510B6 (es)
DE (2) DE19934433A1 (es)
DK (1) DK1198453T5 (es)
ES (1) ES2192535T3 (es)
HK (1) HK1048636B (es)
HU (1) HUP0201988A3 (es)
MX (1) MXPA02000730A (es)
MY (1) MY122531A (es)
NO (1) NO322154B1 (es)
PL (1) PL201893B1 (es)
PT (1) PT1198453E (es)
RU (1) RU2251548C2 (es)
SK (1) SK286066B6 (es)
UA (1) UA73518C2 (es)
WO (1) WO2001007435A2 (es)
ZA (1) ZA200201486B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589954B1 (en) 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
IL146309A (en) 1999-05-21 2008-03-20 Scios Inc Derivatives of the indole type and pharmaceutical preparations containing them as inhibitors of kinase p38
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
US20020156453A1 (en) * 1999-10-14 2002-10-24 Pettis Ronald J. Method and device for reducing therapeutic dosage
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20020095134A1 (en) * 1999-10-14 2002-07-18 Pettis Ronald J. Method for altering drug pharmacokinetics based on medical delivery platform
DE10102053A1 (de) * 2001-01-17 2002-07-18 Merck Patent Gmbh Piperazinylcarbonylchinoline und -isochinoline
ES2268113T3 (es) 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag Derivados de 4-piperazinilindol con afinidad al receptor 5-ht6.
BR0210628A (pt) * 2001-06-29 2004-08-10 Becton Dickinson Co Liberação intradérmica de vacinas e agentes terapêuticos genéticos via microcânula
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
GB0203811D0 (en) * 2002-02-18 2002-04-03 Glaxo Group Ltd Compounds
DE10212564B4 (de) * 2002-03-12 2007-04-19 Neurobiotec Gmbh 1-Allyl-ergotalkaloid-Derivate und ihre Verwendung zur Prophylaxe und Therapie von Migräne
DE10217006A1 (de) * 2002-04-16 2003-11-06 Merck Patent Gmbh Substituierte Indole
WO2004020014A2 (en) * 2002-08-30 2004-03-11 Becton, Dickinson And Company Method of controlling pharmacokinetics of immunomodulatory compounds
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten
US20050163711A1 (en) * 2003-06-13 2005-07-28 Becton, Dickinson And Company, Inc. Intra-dermal delivery of biologically active agents
CA2536669A1 (en) * 2003-08-26 2005-03-17 Becton, Dickinson And Company Methods for intradermal delivery of therapeutics agents
WO2005091922A2 (en) * 2004-03-03 2005-10-06 Becton, Dickinson And Company Methods and devices for improving delivery of a substance to skin
EP1755605A2 (en) * 2004-04-15 2007-02-28 Samaritan Pharmaceuticals, Inc. Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
US20050256182A1 (en) * 2004-05-11 2005-11-17 Sutter Diane E Formulations of anti-pain agents and methods of using the same
DE102004047517A1 (de) * 2004-09-28 2006-03-30 Merck Patent Gmbh Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
DK1831159T3 (da) * 2004-12-21 2010-03-22 Hoffmann La Roche Tetralin og indanderivater samt anvendelser deraf
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
JP2009536208A (ja) * 2006-05-05 2009-10-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 結晶性（３−シアノ−１ｈ−インドール−７−イル）−［４−（４−フルオロフェネチル）ピペラジン−１−イル］メタノンホスフェート
US7514433B2 (en) * 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
CA2686547C (en) * 2007-05-14 2015-12-08 Sk Holdings Co., Ltd. Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound
EP2008656A1 (en) * 2007-06-28 2008-12-31 Bergen Teknologioverforing AS Compositions for the treatment of hyperphenylalaninemia
ES2421237T7 (es) * 2007-08-15 2013-09-30 Arena Pharmaceuticals, Inc. Derivados de imidazo[1,2-a]piridin como moduladores del receptor serotoninérgico 5ht2a en el tratamiento de trastornos relacionados con el mismo
KR101062376B1 (ko) * 2008-04-10 2011-09-06 한국화학연구원 신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
US9308323B2 (en) 2011-11-15 2016-04-12 Smiths Medical Asd, Inc. Systems and methods for illuminated medical tubing detection and management indicating a characteristic of at least one infusion pump
RU2549963C1 (ru) * 2014-04-08 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дальневосточный государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО "ДВГМУ" Минздрава России) Способ прогнозирования развития критической печеночной недостаточности на основании сывороточного уровня селена
GB2554371B (en) * 2016-09-22 2019-10-09 Resolute Energy Solutions Ltd Well apparatus and associated methods

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0309263B1 (en) 1987-09-24 1994-03-09 Jencap Research Limited Hormone composition and use
US5093341A (en) * 1987-12-17 1992-03-03 Merrell Dow Pharmaceuticals Inc. N-aralkyl piperidine derivatives useful as antithrombolytic agents
US5032604A (en) * 1989-12-08 1991-07-16 Merck & Co., Inc. Class III antiarrhythmic agents
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5330986A (en) 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
ZA954689B (en) 1994-06-08 1996-01-29 Lundbeck & Co As H 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines
JP2001506230A (ja) 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
GB9718712D0 (en) * 1997-09-03 1997-11-12 Merck Sharp & Dohme Theraputic Agents
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
DE19934432A1 (de) * 1999-07-22 2001-02-01 Merck Patent Gmbh Indolderivate
WO2005099240A1 (ja) * 2004-04-07 2005-10-20 Matsushita Electric Industrial Co., Ltd. 情報交換支援装置、情報交換支援方法、及び情報交換支援プログラム

Also Published As

Publication number Publication date
KR20020019513A (ko) 2002-03-12
WO2001007435A3 (de) 2001-08-16
DE50001729D1 (de) 2003-05-15
RU2251548C2 (ru) 2005-05-10
CZ300510B6 (cs) 2009-06-03
MXPA02000730A (es) 2002-08-20
AR024819A1 (es) 2002-10-23
ATE236877T1 (de) 2003-04-15
AU6270400A (en) 2001-02-13
MY122531A (en) 2006-04-29
AU770411B2 (en) 2004-02-19
SK286066B6 (sk) 2008-02-05
NO20020307D0 (no) 2002-01-21
JP2003505458A (ja) 2003-02-12
NO322154B1 (no) 2006-08-21
EP1198453A2 (de) 2002-04-24
SK512002A3 (en) 2002-05-09
WO2001007435A2 (de) 2001-02-01
CZ200268A3 (cs) 2002-04-17
HK1048636B (zh) 2006-08-11
HUP0201988A2 (hu) 2002-11-28
PL353446A1 (en) 2003-11-17
DK1198453T5 (da) 2005-01-31
UA73518C2 (en) 2005-08-15
DE19934433A1 (de) 2001-01-25
NO20020307L (no) 2002-03-21
HK1048636A1 (en) 2003-04-11
ZA200201486B (en) 2003-07-30
JP2012006940A (ja) 2012-01-12
JP5242871B2 (ja) 2013-07-24
US7084143B2 (en) 2006-08-01
CN1229345C (zh) 2005-11-30
US6838461B1 (en) 2005-01-04
EP1198453B1 (de) 2003-04-09
PT1198453E (pt) 2003-08-29
CN1364157A (zh) 2002-08-14
CA2383779A1 (en) 2001-02-01
BR0012607A (pt) 2002-04-09
US20050096330A1 (en) 2005-05-05
KR100779207B1 (ko) 2007-11-27
PL201893B1 (pl) 2009-05-29
HUP0201988A3 (en) 2003-12-29
DK1198453T3 (da) 2003-07-21
CA2383779C (en) 2011-03-29
EP1198453B9 (de) 2004-11-10

Similar Documents

Publication Publication Date Title
ES2192535T3 (es) Derivados de n-(indolcarbonil)-piperazina como ligandos del receptor 5-ht2a.
CO5640136A2 (es) Derivados de hexahidropiridoisoquinolinas inhibidores de dpp-iv y composiciones farmaceuticas que los contienen
AR053186A1 (es) Derivados del 1- bencil indol carboxamida
NZ332960A (en) tetrahydro-cyclopropan[c]benz[e]-indol-4-one and tetrahydro-cyclopropan[c]benzo[e]-indole derivatives and medicaments
BRPI0414817A (pt) derivados de ácido indol substituìdos e seu uso como inibidores de pai-l
CO5630029A2 (es) Derivados de indol e indolina sustituidos
TR199902590T2 (xx) Birle�ik 5HT1A 5HT1B ve 5HT1D resept�r antagonist aktivitesi olan indol t�revleri.
ES2192183T3 (es) Derivados de imidazopiridina como inhibidores de fosfodiesterasa vii.
PE20081658A1 (es) Derivados indolicos con anillo unido en las posiciones 5,6 y sus metodos de uso
AR002746A1 (es) Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos.
ECSP066967A (es) Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos
ECSP088150A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR040694A1 (es) Derivados de benzodioxol como antagonistas de los receptores cb1
ES2476422T3 (es) Compuestos de piperidina 3,5-sustituida como inhibidores de renina
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
DK0594702T3 (da) Substituerede indoler som midler mod AIDS
AR026351A1 (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii
ES2195382T3 (es) Compuestos indolcarboxilicos y su uso como compuestos farmaceuticos.
DE60021194D1 (de) Phenylpiperazin-derivate als inhibitoren der serotonin-wiederaufnahme
ES2080815T3 (es) Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen.
CO5050296A1 (es) Derivados de 1-arenosulfonil-2-arilo-pirrolidina y de piperidina
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
CO4970719A1 (es) Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
DK65780A (da) Piperidinopropylderivater fremgangsmaader til deres fremstilling og laegemidler indeholdnde disse forbindelser
AR013090A1 (es) Composicion farmaceutica para el tratamiento del cancer o de un trastorno proliferativo benigno, procedimiento para el tratamiento del cancer o de untrastorno proliferativo benigno, composicion farmaceutica para inhibir el desarrollo anormal de celulas en un mamifero